UPL (UPL) Q4 25/26 & CMD 2026 earnings summary

Executive summary

• Delivered record financial performance in FY26, with strong revenue, EBITDA, and net income growth across all platforms, outperforming guidance despite global volatility and sector headwinds.

• Strategic focus on operational excellence, capital allocation, innovation, and sustainability drove margin expansion and improved business resilience.

• Deleveraging and disciplined cash management significantly strengthened the balance sheet and reduced gearing ratios.

• Transformation initiatives, digitalization, and restructuring enhanced efficiency, customer engagement, and future readiness.

• Statutory auditors issued an unmodified opinion on consolidated and standalone results.

Financial highlights

• FY26 revenue grew 11% year-over-year to ₹51,839 crore, exceeding guidance and driven by volume growth across key markets.

• EBITDA increased 18% to ₹9,588 crore, with margin improving to 19.9% (22% adjusted for provisions); margin expansion of 110 bps to 18.5%.

• Net profit attributable to owners for FY26 was ₹3,573 crore, a significant increase from ₹862 crore in FY25; PATMI rose 114% to ₹1,921 crore.

• Contribution margin improved by 220 basis points to 41.2%; all platforms contributed to margin expansion.

• Gross debt reduced by $850 million, net debt by $400 million to $1,616 million; gearing ratio dropped below 1.6x.

• Free cash flow to equity improved by over ₹3,000 crore year-over-year; healthy free cash flow of ₹3,226 crore generated.

Outlook and guidance

• Q1 FY27 revenue growth guided at 10%-14%, EBITDA growth at 14%-18%, reflecting cautious optimism amid ongoing macro uncertainties.

• Focus remains on portfolio rationalization, plant utilization, and quality of earnings, with continued organic growth and margin expansion via innovation.

• Medium-term net debt/EBITDA target set at 1.2-1.5x, with ongoing evaluation of optimal capital structure.

• CapEx for FY27 expected at $300-$350 million, prioritizing specialty chemicals and backward integration.

• Major restructuring underway, including mergers and demergers, pending regulatory approvals; no effect in FY26 results.